ID: ALA222384

Max Phase: Preclinical

Molecular Formula: C20H19N3O

Molecular Weight: 317.39

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC(=O)Nc1cc(-c2ccccc2)nc(-c2ccccc2)n1

Standard InChI:  InChI=1S/C20H19N3O/c1-2-9-19(24)22-18-14-17(15-10-5-3-6-11-15)21-20(23-18)16-12-7-4-8-13-16/h3-8,10-14H,2,9H2,1H3,(H,21,22,23,24)

Standard InChI Key:  UBJLQDSZSYHXLE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 317.39

Molecular Weight (Monoisotopic): 317.1528

AlogP: 4.55

#Rotatable Bonds: 5

Polar Surface Area: 54.88

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.88

CX Basic pKa: 2.50

CX LogP: 5.47

CX LogD: 5.47

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.75

Np Likeness Score: -1.39

References

1. Chang LC, Spanjersberg RF, von Frijtag Drabbe Künzel JK, Mulder-Krieger T, van den Hout G, Beukers MW, Brussee J, Ijzerman AP..  (2004)  2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists.,  47  (26): [PMID:15588088] [10.1021/jm049448r]

2. Yaziji V, Rodríguez D, Gutiérrez-de-Terán H, Coelho A, Caamaño O, García-Mera X, Brea J, Loza MI, Cadavid MI, Sotelo E..  (2011)  Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists.,  54  (2): [PMID:21186795] [10.1021/jm100843z]

Source

Source(1):

• Scientific Literature